Peptide Safety

Discussions of peptide safety collapse four distinct questions into one. Separating them makes the topic tractable.

• Molecular safety: what does the pharmacology do at relevant exposures?
• Product safety: is this vial what the label says, sterile, and free of contaminants?
• Context safety: is it being used in a population and setting where risks are monitored?
• Evidence safety: has anyone measured harm systematically, and for how long?

Adverse effects are only found when someone looks for them in a structured way. For compounds studied mainly in animals or sold outside regulated channels, no surveillance system exists, so an absence of reports carries almost no information.

Approved medicines look 'less safe' on paper partly because their risks have actually been catalogued.

For unapproved peptide products, documented problems include incorrect content, degraded material, bacterial endotoxin, non-sterile filling, and mislabelled concentration. These risks exist independently of the peptide's own pharmacology.